Hypothesis\n\nThe suprachiasmatic nucleus (SCN) harbors a transcriptional network that regulates genome-wide epigenetic fidelity via rhythmic release of neuroendocrine factors (e.g., vasopressin, TGF‑α) that modulate DNA methyltransferase activity and histone acetylation in peripheral tissues. Age‑related dampening of SCN electrical output reduces these signals, leading to stochastic epigenetic drift that manifests as the hallmarks of aging. Restoring SCN‑derived rhythmic signaling should re‑synchronize peripheral epigenetic clocks and delay multiple aging phenotypes.\n\n## Mechanistic Rationale\n\n1. SCN neurons secrete vasoactive intestinal peptide (VIP) and arginine vasopressin (AVP) in a circadian manner; these peptides bind G‑protein coupled receptors on astrocytes and peripheral cells, activating cAMP/PKA pathways that phosphorylate DNMT1 and HDACs, thereby influencing methylation and acetylation rhythms.\n2. Loss of SCN rhythmic output diminishes cyclic phosphorylation of DNMT1, causing its mislocalization and passive demethylation during DNA replication, which accumulates as epigenetic noise.\n3. This epigenetic noise disrupts expression of proteostasis chaperones, mitochondrial biogenesis factors, and senescence‑associated secretory phenotype (SASP) regulators, producing the observed hallmarks.\n\n## Testable Predictions\n\n- Prediction 1: Targeted AAV9‑mediated overexpression of Vip or Avp specifically in the SCN of aged mice will restore circadian amplitude of peripheral DNA methylation rhythms (measured by longitudinal blood‑based epigenetic clocks) within 4 weeks.\n- Prediction 2: Such SCN‑specific rescue will improve at least two downstream hallmarks: (a) increased hepatic proteasome activity (reduced ubiquitinated protein load) and (b) enhanced skeletal muscle mitochondrial respiration (higher OXPHOS capacity) compared to AAV‑GFP controls.\n- Prediction 3: Disrupting SCN signaling via chemogenetic inhibition (hM4Di DREADDs) in young adult mice will accelerate epigenetic clock progression and induce premature hallmarks, reversible by exogenous VIP/AVP infusion.\n\n## Experimental Design\n\n- Use adult (12‑month) C57BL/6 mice; inject AAV9‑Syn‑VIP or AAV9‑Syn‑AVP unilaterally into the SCN via stereotaxic surgery; control receives AAV9‑Syn‑GFP.\n- Monitor circadian behavior (wheel running) and collect plasma monthly for epigenetic clock (e.g., Horvath mouse clock) via targeted bisulfite sequencing.\n- At 4‑ and 8‑week post‑injection, harvest liver and quadriceps for proteasome activity assays (fluorogenic substrate) and mitochondrial respiration (Seahorse XF).\n- Additionally, perform RNA‑seq to assess expression of chaperones (Hsp70, Hsp90), mitochondrial genes (Ppargc1a, Nrf1), and SASP cytokines (Il6, Tnf).\n- Statistical analysis: two‑way ANOVA (treatment × time) with post‑hoc Tukey; n≥10 per group for adequate power.\n\n## Falsifiability\n\nIf SCN‑specific VIP/AVP overexpression fails to restore peripheral epigenetic rhythmicity or does not ameliorate proteostatic and mitochondrial hallmarks, the hypothesis that a central circadian‑epigenetic controller drives systemic aging would be refuted, suggesting that observed correlations are epiphenomenal or that other upstream regulators dominate.
